Related Experiment Video
Updated: Jun 27, 2025
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer
Ernest Moles1,2,3,4, David W Chang1,2,3, Friederike M Mansfeld1,2,3
1Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, 2052, Australia.
Introduction:
Despite improvements in chemotherapy and molecularly targeted therapies, the life expectancy of patients with advanced non-small cell lung cancer (NSCLC) remains less than 1 year. There is thus a major global need to advance new treatment strategies that are more effective for NSCLC. Drug delivery using liposomal particles has shown success at improving the biodistribution and bioavailability of chemotherapy. Nevertheless, liposomal drugs lack selectivity for the cancer cells and have a limited ability to penetrate the tumor site, which severely limits their therapeutic potential. Epidermal growth factor receptor (EGFR) is overexpressed in NSCLC tumors in about 80% of patients, thus representing a promising NSCLC-specific target for redirecting liposome-embedded chemotherapy to the tumor site.
Methods:
Herein, we investigated the targeting of PEGylated liposomal doxorubicin (Caelyx), a powerful off-the-shelf antitumoral liposomal drug, to EGFR as a therapeutic strategy to improve the specific delivery and intratumoral accumulation of chemotherapy in NSCLC. EGFR-targeting of Caelyx was enabled through its complexing with a polyethylene glycol (PEG)/EGFR bispecific antibody fragment. Tumor targeting and therapeutic potency of our treatment approach were investigated in vitro using a panel of NSCLC cell lines and 3D tumoroid models, and in vivo in a cell line-derived tumor xenograft model.
Results:
Combining Caelyx with our bispecific antibody generated uniform EGFR-targeted particles with improved binding and cytotoxic efficacy toward NSCLC cells. Effects were exclusive to cancer cells expressing EGFR, and increments in efficacy positively correlated with EGFR density on the cancer cell surface. The approach demonstrated increased penetration within 3D spheroids and was effective at targeting and suppressing the growth of NSCLC tumors in vivo while reducing drug delivery to the heart.
Conclusion:
EGFR targeting represents a successful approach to enhance the selectivity and therapeutic potency of liposomal chemotherapy toward NSCLC.
Insights
Targeting epidermal growth factor receptor (EGFR) with liposomal chemotherapy enhances drug delivery and efficacy in non-small cell lung cancer (NSCLC). This strategy improves tumor targeting and suppresses tumor growth while minimizing off-target effects.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Advanced non-small cell lung cancer (NSCLC) has a poor prognosis despite current therapies.
- Liposomal drug delivery improves chemotherapy bioavailability but lacks tumor specificity.
- Epidermal growth factor receptor (EGFR) is overexpressed in 80% of NSCLC cases, presenting a viable therapeutic target.
Purpose of the Study:
- To develop an EGFR-targeted liposomal chemotherapy for improved NSCLC treatment.
- To enhance the selective delivery and intratumoral accumulation of chemotherapy in NSCLC.
Main Methods:
- PEGylated liposomal doxorubicin (Caelyx) was complexed with an EGFR bispecific antibody fragment.
- In vitro studies used NSCLC cell lines and 3D tumoroid models.
- In vivo efficacy was assessed in a cell line-derived tumor xenograft model.
Main Results:
- EGFR-targeted Caelyx demonstrated enhanced binding and cytotoxicity against NSCLC cells, correlated with EGFR expression levels.
- The targeted liposomes showed increased penetration in 3D tumor models.
- In vivo studies confirmed effective NSCLC tumor growth suppression with reduced cardiac drug delivery.
Conclusions:
- EGFR targeting significantly enhances the selectivity and therapeutic efficacy of liposomal chemotherapy for NSCLC.
- This approach offers a promising strategy to improve outcomes for NSCLC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...